Olympus (7733) AI Stock Analysis

• Market Cap: $1.93T
• Dividend Yield: 1.14%
• Average Volume (3M): 3.95M
• Price to Earnings (P/E): 17.4
• Beta (1Y): 0.81
• Revenue Growth: 0.59%
• EPS Growth: 557.87%
• Country: JP
• Employees: 28,838
• Sector: Healthcare
• Sector Strength: 43
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 7.97
• Shares Outstanding: 1,139,116,300
• 10 Day Avg. Volume: 4,549,100
• 30 Day Avg. Volume: 3,948,030
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.02
• Enterprise Value/Revenue: 1.97
• Enterprise Value/Gross Profit: 2.88
• Enterprise Value/Ebitda: 8.58
• 1Y Price Target: $2,085.42
• Price Target Upside: 18.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 8

• Rating: 69 Neutral
• Price Target: ¥1,881.00 ▲(6.94% Upside)

Olympus's strong financial performance is the primary driver of its stock score, supported by solid revenue and cash flow growth. However, the technical analysis indicates a bearish trend, limiting the stock's upward potential. The valuation is reasonable, offering moderate income potential through dividends.

Olympus Business Overview & Revenue Model

Company Description

Olympus Corporation manufactures and sells precision machineries and instruments worldwide. It operates through four segments: Endoscopic Solutions Business, Therapeutic Solutions Business, Scientific Solutions Business, and Others. The Endoscopic Solutions Business segment offers gastrointestinal and surgical endoscopes, endoscopy system, and repair services. The Therapeutic Solutions Business segment provides urology, gynecology, ear, nose, and throat products; endo-therapy and energy devices; and surgical single-use devices. The Scientific Solutions Business segment offers biological and industrial microscopes, industrial endoscopes and videoscopes, non-destructive testing equipment, and X-ray fluorescence (XRF) analyzers. The Others segment offers biomedical materials and orthopedic equipment. The company also offers medical devices, such as surgical microscopes, endoscope reprocessors, electrosurgical devices, and respiratory-endotherapy devices, as well as system integration and maintenance/services. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was founded in 1919 and is headquartered in Tokyo, Japan.

How the Company Makes Money

Olympus makes money primarily through the sale of its medical systems, scientific solutions, and industrial equipment. The largest revenue stream comes from its medical business, especially the sales of endoscopic devices and related surgical equipment used in minimally invasive procedures. The company also generates revenue from its scientific solutions division, which includes microscopes and other laboratory equipment used in research and development. Additionally, Olympus has a significant presence in the industrial sector, offering products such as non-destructive testing equipment and industrial microscopes. Partnerships with hospitals, research institutions, and industrial firms contribute significantly to its earnings, alongside continuous investment in research and development to innovate and maintain its competitive edge in technology and healthcare markets.

Olympus Financial Statement Overview

Summary

Olympus demonstrates robust financial health with strong revenue and cash flow growth. The company maintains solid profitability metrics and efficient cost management, despite some fluctuations in net income and free cash flow.

Income Statement

Olympus has demonstrated a strong revenue growth rate, with consistent annual increases culminating in a 6.52% growth in 2025. The company's gross profit margin remains robust, consistently above 67% in recent years, which indicates efficient cost management. The net profit margin improved significantly in 2025 compared to previous years. EBIT and EBITDA margins are healthy, showcasing strong operational performance. However, fluctuations in net income, particularly the drop in 2024, highlight some volatility in profitability.

Balance Sheet

The balance sheet shows a solid equity position with an improving equity ratio, reaching 52.45% in 2025, indicating financial stability. The debt-to-equity ratio decreased, reflecting effective debt management. Return on equity has been strong, though it experienced fluctuations due to varying net income levels. The company's leverage has been reduced over recent years, enhancing financial flexibility.

Cash Flow

Olympus has shown impressive growth in free cash flow, particularly in 2025, following a challenging 2024. The operating cash flow to net income ratio is favorable, indicating efficient cash generation relative to profits. The company has maintained a positive free cash flow, demonstrating strong cash management. However, the fluctuations in free cash flow highlight potential volatility in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	997.33B	997.33B	936.21B	881.92B	868.87B	730.54B
Gross Profit	683.70B	683.70B	625.12B	596.85B	571.70B	459.53B
EBITDA	229.58B	231.90B	112.10B	238.82B	233.16B	160.81B
Net Income	117.86B	117.86B	242.57B	143.43B	115.74B	12.92B
Balance Sheet
Total Assets	1.43T	1.43T	1.53T	1.51T	1.36T	1.18T
Cash, Cash Equivalents and Short-Term Investments	252.53B	252.53B	340.93B	180.69B	312.84B	227.75B
Total Debt	229.10B	229.10B	299.62B	340.06B	386.13B	355.26B
Total Liabilities	681.09B	681.09B	777.03B	867.07B	846.64B	785.54B
Stockholders Equity	751.73B	751.73B	757.19B	640.09B	510.17B	394.33B
Cash Flow
Free Cash Flow	144.46B	144.46B	-22.26B	27.87B	107.96B	64.89B
Operating Cash Flow	190.46B	190.46B	42.37B	98.49B	169.73B	124.12B
Investing Cash Flow	-65.47B	-65.47B	359.99B	-58.41B	-71.02B	-118.92B
Financing Cash Flow	-211.54B	-211.54B	-276.01B	-143.18B	-40.67B	40.80B

Olympus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1759.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7733, the sentiment is Negative. The current price of 1759 is below the 20-day moving average (MA) of 1775.98, below the 50-day MA of 1787.08, and below the 200-day MA of 2074.87, indicating a bearish trend. The MACD of 4.55 indicates Positive momentum. The RSI at 48.21 is Neutral, neither overbought nor oversold. The STOCH value of 52.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7733.

Olympus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7733	69 Neutral	$1.93T	17.42	14.88%	1.14%	0.59%	557.87%
Sector *	57 Neutral	£5.18B	4.93	-44.55%	2.33%	28.89%	-10.08%
TRUMF	―	$27.49B	32.97	9.17%	1.01%	―	―
AHICF	―	$4.55B	64.47	7.09%	0.93%	―	―
HOCPF	―	$44.75B	32.69	21.19%	0.83%	―	―
5FA	―	€1.41B	39.08	2.49%	―	―	―
SSMXF	―	$8.77B	26.12	10.48%	1.53%	―	―

Olympus Corporate Events

Olympus Reports Decline in Q1 Financial Performance Amid Business Adjustments

Olympus Corporation reported a significant decline in its financial performance for the three months ending June 30, 2025, with revenue and profits dropping compared to the previous year. The company’s revenue fell by 12.1%, and operating profit decreased by 39.6%, largely due to the classification of its Orthopedic Business as a discontinued operation. Despite these challenges, Olympus has revised its full-year forecast, expecting minimal revenue growth but a notable decline in profits, reflecting ongoing adjustments in its business operations.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Progress in Share Repurchase Program

Olympus Corporation announced the status of its share repurchase program, having repurchased 2,114,500 common shares for approximately JPY 3.83 billion between July 28 and July 31, 2025. This move is part of a broader plan approved by the Board of Directors to repurchase up to 36 million shares, valued at a maximum of JPY 50 billion, by October 31, 2025, which is intended to enhance shareholder value and optimize capital structure.

The most recent analyst rating on (JP:7733) stock is a Buy with a Yen3300.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Partners with Revival Healthcare for Endoluminal Robotics Venture

Olympus Corporation has announced a joint venture with Revival Healthcare Capital to develop endoluminal robotic surgery products through Swan EndoSurgical, Inc. This strategic investment aims to strengthen Olympus’s position in the MedTech industry by capitalizing on the growing market for minimally invasive surgical solutions, with potential investments reaching up to $458 million over six years. The venture underscores Olympus’s commitment to advancing medical technology and improving patient outcomes.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reports FY2025 Financial Results Amid Business Reorganization

Olympus has reported its financial results for FY2025, highlighting a reorganization of its business segments and the divestiture of its orthopedic business. The company recorded a gain from the sale of its Evident operation in FY2024 Q1 and anticipates further changes as it transitions its focus towards gastrointestinal and surgical solutions, impacting its financial reporting and market strategy.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Announces Share Repurchase and Cancellation Plan

Olympus Corporation announced a strategic move to repurchase up to 36 million of its common shares, representing 3.19% of its outstanding shares, with a maximum expenditure of 50 billion yen. This decision aims to enhance shareholder returns and improve capital efficiency, with the repurchase scheduled between July and October 2025, followed by the cancellation of the repurchased shares in November 2025, excluding those allocated for stock compensation.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

Olympus Reports Strong Operating Profit Amidst Strategic Restructuring

Olympus Corporation reported a significant increase in operating profit for the fiscal year ended March 31, 2025, despite a decline in total comprehensive income. The company has classified its Orthopedic Business as a discontinued operation, impacting the financial results. The forecast for the next fiscal year indicates a slight increase in revenue, but a decrease in operating profit and profit attributable to owners. The company also announced changes in its consolidation scope, including the addition of Olympus Corporation Chile and the exclusion of two other companies.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2600.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.